Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.
|Articles|September 3, 2014
Evidence-Based Practices in Managing Agitation and Aggression
Author(s)Leslie L. Citrome, MD, MPH
A video summarizing key points of a presentation titled “Agitation and Aggression: Managing the Acute Episode and Beyond, An Evidence-Based Approach.”
Advertisement
Here to discuss evidence-based practices in
Dr Citrome is a scheduled speaker at this year's US Psychiatric and Mental Health Congress in Orlando, Florida. His presentation is titled “Agitation and Aggression: Managing the Acute Episode and Beyond, An Evidence-Based Approach.”
Advertisement
Related to this article
Antipsychotic levels clarify adherence, guide dose escalation up to a point of futility, and offer more than pharmacogenetic testing, says Jonathan Meyer, MD.
How to interpret antipsychotic drug levels in schizophrenia: when labs mislead, when levels help adherence and toxicity checks, and why serial monitoring matters.
Therapeutic drug monitoring takes guesswork out of antipsychotic care—spotting nonadherence, guiding dose targets, and defining response thresholds and the “point of futility” in schizophrenia.
Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.
Neflamapimod misses its main DLB endpoint, but biomarker and subgroup signals suggest IL-1β pathway impact and may justify a phase 3 trial.
A systematic review and meta-analysis compares pharmacological agents with nonpharmacologic approaches to identify the most effective interventions for insomnia in peri- and postmenopausal women.
National survey shows most US adults don’t know AUD medications exist, and safety concerns plus racial disparities shape hesitation toward treatment.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Burnout, Gratitude, and the Value of Staying Current: On the Mind of Gus Alva, MD, DFAPA
2
Daridorexant, Orexin Receptor Agonist, Shows Positive Results in Pediatric Insomnia
3
Food Noise and GLP-1 Drugs: What Research Reveals About Motivation and Appetitive Drive
4
Dementia Pipeline Update: Phase 2 and 3 Developments in Alzheimer Disease and Lewy Body Dementia
5